(Q35503563)

8 August 2017

title

A systematic review of economic evaluations of chemoprophylaxis for tuberculosis (English)

1 reference

8 August 2017

1 reference

Shraddha Chavan

1

1 reference

8 August 2017

David Newlands

series ordinal

2

1 reference

8 August 2017

Cairns Smith

series ordinal

3

1 reference

8 August 2017

publication date

1 November 2011

1 reference

Journal of Tropical Medicine

8 August 2017

published in

1 reference

8 August 2017

volume

2011

1 reference

8 August 2017

page(s)

130976

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Oxygen therapy for cystic fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Generalized cost-effectiveness analysis for national-level priority-setting in the health sector

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Clinical practice. Latent tuberculosis infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Isoniazid-related fatal hepatitis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

School-based screening for tuberculous infection. A cost-benefit analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

The burden of disease, economic costs and clinical consequences of tuberculosis in the Philippines

27 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Donor funding priorities for communicable disease control in the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Cost-effectiveness of isoniazid chemoprevention in close contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F130976

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206325

Cost-effectiveness of LTBI treatment for TB contacts in British Columbia

26 September 2018

1 reference

12 December 2020

Developing a scoring system to quality assess economic evaluations

1 reference

12 December 2020

Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age?

1 reference

12 December 2020

Treatment of tuberculosis and other mycobacterial diseases

1 reference

12 December 2020

A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/130976

1 reference

release_yq6mktxsu5cwjptc2rzpmijhfu

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yq6mktxsu5cwjptc2rzpmijhfu

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3206325

1 reference

8 August 2017

1 reference